Key facts
- Notable investors include SOSV, IndieBio, Peachscore, Peachscore + Gust Accelerator Program.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Sable Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Sable Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sable Therapeutics
Operator of a biotherapeutic delivery system intended for targeted fat treatment applications. The company uses a nanomedicine-based mechanism capable of transporting therapeutic payloads directly to adipose tissue, enabling clients to improve treatment precision, reduce systemic exposure, enhance drug efficacy, and integrate seamlessly with existing fat-reduction therapies.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 2
- Website
- sabletherapeutics.com/
- Ownership
- Privately Held (backing)
Sable Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sable Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sable Therapeutics in its N-PORT filings yet. We sweep new filings monthly.